{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-051047","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.202650+00:00","generated_at":"2026-06-09T01:25:10.999143+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis Q3 2023 revenue $144M, net loss $143M; eplontersen on track for Dec 2023 U.S. approval","bullets":["Total revenue $144M (-10% YoY); SPINRAZA royalties $67M flat; R&D revenue $60M down from $87M.","Operating expenses $287M (+31% YoY); loss from operations $143M vs. $59M loss in Q3 2022.","Cash and short-term investments $2.2B; reaffirmed 2023 financial guidance.","Eplontersen regulatory submissions accepted in EU and Canada; potential U.S. approval in Dec 2023.","Olezarsen Phase 3 Balance study met endpoints: significant triglyceride lowering, reduced pancreatitis attacks; on track for early 2024 filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-051047","json":"https://secwatch.observer/filing/0001140361-23-051047.json","markdown":"https://secwatch.observer/filing/0001140361-23-051047.md","text":"https://secwatch.observer/filing/0001140361-23-051047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036123051047/0001140361-23-051047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036123051047/ef20013902_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:25:10.999143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"381996fd1c14315f1855e19e60a92a0432c837ff","claim":"IONIS PHARMACEUTICALS INC updated its the third quarter of 2023 guidance (reaffirmed).","evidence_excerpt":"today reported financial results for the third quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036123051047/0001140361-23-051047-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}